Frontiers in Neurology (Jan 2021)
The European Reference Network for Rare Neurological Diseases
- Carola Reinhard,
- Carola Reinhard,
- Anne-Catherine Bachoud-Lévi,
- Anne-Catherine Bachoud-Lévi,
- Anne-Catherine Bachoud-Lévi,
- Tobias Bäumer,
- Tobias Bäumer,
- Enrico Bertini,
- Alicia Brunelle,
- Alicia Brunelle,
- Annemieke I. Buizer,
- Antonio Federico,
- Thomas Gasser,
- Thomas Gasser,
- Samuel Groeschel,
- Sanja Hermanns,
- Sanja Hermanns,
- Thomas Klockgether,
- Ingeborg Krägeloh-Mann,
- G. Bernhard Landwehrmeyer,
- Isabelle Leber,
- Isabelle Leber,
- Alfons Macaya,
- Caterina Mariotti,
- Wassilios G. Meissner,
- Wassilios G. Meissner,
- Maria Judit Molnar,
- Jorik Nonnekes,
- Juan Dario Ortigoza Escobar,
- Belen Pérez Dueñas,
- Lori Renna Linton,
- Ludger Schöls,
- Rebecca Schuele,
- Rebecca Schuele,
- Marina A. J. Tijssen,
- Rik Vandenberghe,
- Rik Vandenberghe,
- Anna Volkmer,
- Anna Volkmer,
- Nicole I. Wolf,
- Holm Graessner,
- Holm Graessner
Affiliations
- Carola Reinhard
- Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
- Carola Reinhard
- Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany
- Anne-Catherine Bachoud-Lévi
- Assistance Publique-Hôpitaux de Paris, National Reference Center for Huntington's Disease, Neurology Department, Henri Mondor-Albert Chenevier Hospital, Créteil, France
- Anne-Catherine Bachoud-Lévi
- Département d'Etudes Cognitives, École normale supérieure, PSL University, Paris, France
- Anne-Catherine Bachoud-Lévi
- Inserm U955, Institut Mondor de Recherche Biomédicale, Equipe E01 NeuroPsychologie Interventionnelle, Créteil, France
- Tobias Bäumer
- Institute of Systems Motor Science, University of Lübeck, Lübeck, Germany
- Tobias Bäumer
- Centre for Rare Diseases, University of Lübeck, Lübeck, Germany
- Enrico Bertini
- Unit of Neuromuscular and Neurodegenerative Disorders and Genetics and Rare Diseases Research Division, Bambino Gesù Children's Research Hospital, Instituto de Ricovero e Cura a Carattere Scientifico, Rome, Italy
- Alicia Brunelle
- Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
- Alicia Brunelle
- Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany
- Annemieke I. Buizer
- Department of Rehabilitation Medicine, Amsterdam Movement Sciences and Emma Children's Hospital, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
- Antonio Federico
- 0Department of Medicine, Neurology, and Neurosciences, Medical School, University of Siena, Siena, Italy
- Thomas Gasser
- 1Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
- Thomas Gasser
- 2German Center for Neurodegenerative Diseases, Tübingen, Germany
- Samuel Groeschel
- 3Department of Paediatric Neurology and Developmental Medicine, University Children's Hospital, Tübingen, Germany
- Sanja Hermanns
- Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
- Sanja Hermanns
- Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany
- Thomas Klockgether
- 4Department of Neurology, University Hospital Bonn, Bonn, Germany
- Ingeborg Krägeloh-Mann
- 3Department of Paediatric Neurology and Developmental Medicine, University Children's Hospital, Tübingen, Germany
- G. Bernhard Landwehrmeyer
- 5University of Ulm, Department of Neurology, Ulm, Germany
- Isabelle Leber
- 6Sorbonne Universités, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France
- Isabelle Leber
- 7Reference Centre for Rare or Early Dementias, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France
- Alfons Macaya
- 8Pediatric Neurology Department, Vall d'Hebron Research Institute and Neuroscience Institute, Autonomous University Barcelona, Barcelona, Spain
- Caterina Mariotti
- 9Unit of Medical Genetics and Neurogenetics, Fondazione Instituto de Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy
- Wassilios G. Meissner
- 0CRMR AMS, Service de Neurologie des Maladies Neurodégénératives, CHU Bordeaux, France and Univ. Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France
- Wassilios G. Meissner
- 1Department of Medicine, University of Otago, New Zealand Brain Research Institute, Christchurch, New Zealand
- Maria Judit Molnar
- 2Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary
- Jorik Nonnekes
- 3Department of Rehabilitation, Centre of Expertise for Parkinson and Movement Disorders, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, Netherlands
- Juan Dario Ortigoza Escobar
- 4Movement Disorders Unit, Institut de Recerca Sant Joan de Déu, and Centro de Investigación Biomédica en Red de Enfermedades Raras Instituto de Salud Carlos III (CIBERER-ISCIII), Barcelona, Spain
- Belen Pérez Dueñas
- 5Department of Pediatric Neurology, Hospital Vall d'Hebrón, Pediatric Neurology Research Group at Vall d'Hebrón Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain
- Lori Renna Linton
- 6EuroHSP, Plateforme Maladies Rares, Paris, France
- Ludger Schöls
- 7Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
- Rebecca Schuele
- 2German Center for Neurodegenerative Diseases, Tübingen, Germany
- Rebecca Schuele
- 8Department of Neurodegenerative Diseases, Center of Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
- Marina A. J. Tijssen
- 9Expertise Center Movement Disorders Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
- Rik Vandenberghe
- 0Neurology Service, University Hospitals Leuven, Leuven, Belgium
- Rik Vandenberghe
- 1Laboratory for Cognitive Neurology, Department of Neurosciences, Katholieke Universiteit Leuven, Leuven, Belgium
- Anna Volkmer
- 2Division of Psychology and Language Sciences, University College London, London, United Kingdom
- Anna Volkmer
- 3Department of Therapy Services, University College London Hospitals National Health System Foundation Trust National Hospital for Neurology and Neurosurgery, London, United Kingdom
- Nicole I. Wolf
- 4Department of Child Neurology, Amsterdam Leukodystrophy Centre, Emma Children's Hospital, Amsterdam University Medical Centres, Vrije Universiteit, and Amsterdam Neuroscience, Amsterdam, Netherlands
- Holm Graessner
- Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
- Holm Graessner
- Centre for Rare Diseases, University Hospital Tübingen, Tübingen, Germany
- DOI
- https://doi.org/10.3389/fneur.2020.616569
- Journal volume & issue
-
Vol. 11
Abstract
While rare diseases (RDs) are by definition of low prevalence, the total number of patients suffering from an RD is high, and the majority of them have neurologic manifestations, involving central, peripheral nerve, and muscle. In 2017, 24 European Reference Networks (ERNs), each focusing on a specific group of rare or low-prevalence complex diseases, were formed to improve the care for patients with an RD. One major aim is to have “the knowledge travel instead of the patient,” which has been put into practice by the implementation of the Clinical Patient Management System (CPMS) that enables clinicians to perform pan-European virtual consultations. The European Reference Network for Rare Neurological Diseases (ERN-RND) provides an infrastructure for knowledge sharing and care coordination for patients affected by a rare neurological disease (RND) involving the most common central nervous system pathological conditions. It covers the following disease groups: (i) Cerebellar Ataxias and Hereditary Spastic Paraplegias; (ii) Huntington's disease and Other Choreas; (iii) Frontotemporal dementia; (iv) Dystonia, (non-epileptic) paroxysmal disorders, and Neurodegeneration with Brain Iron Accumulation; (v) Leukoencephalopathies; and (vi) Atypical Parkinsonian Syndromes. At the moment, it unites 32 expert centers and 10 affiliated partners in 21 European countries, as well as patient representatives, but will soon cover nearly all countries of the European Union as a result of the ongoing expansion process. Disease expert groups developed and consented on diagnostic flowcharts and disease scales to assess the different aspects of RNDs. ERN-RND has started to discuss diagnostically unclear patients in the CPMS, is one of four ERNs that serve as foundation of Solve-RD, and has established an RND training and education program. The network will facilitate trial readiness through the establishment of an ERN-RND registry with a minimal data of all patients seen at the ERN-RND centers, thus providing a unique overview of existing genotype-based cohorts. The overall aim of the ERNs is to improve access for patients with RDs to quality diagnosis, care, and treatment. Based on this objective, ERNs are monitored by the European Commission on a regular basis to provide transparency and reassurance to the RD community and the general public.
Keywords
- rare neurological diseases
- standards of care
- training and education
- virtual healthcare
- European reference network